Lintuzumab Satetraxetan AC-225
Lintuzumab Satetraxetan AC-225 Uses, Dosage, Side Effects, Food Interaction and all others data.
Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).
Trade Name | Lintuzumab Satetraxetan AC-225 |
Generic | Lintuzumab satetraxetan AC-225 |
Lintuzumab satetraxetan AC-225 Other Names | 225Ac-HuM195, 225Ac-lintuzumab, Actinium (225ac) lintuzumab satetraxetan, Actinium AC 225 lintuzumab, Actinium AC-225 lintuzumab, Actinium-225-labeled humanized anti-cd33 monoclonal antibody HUM195, HUM-195 AC-225, Lintuzumab actinium Ac-225, Lintuzumab satetraxetan AC-225 |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Lintuzumab Satetraxetan AC-225